46 results about "Kininogen" patented technology

The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H):wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and / or antimicrobial / pharmaceutical composition.

An antimicrobial peptide with heparin binding activity is described. It can be derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acids residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K,R, and H. Also described are pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and / or antimicrobial / pharmaceutical composition.

The invention is concerned with the method for prepareing high purity organism pharmaceutical product, that is, the method of the high purity pancreatic kiniogenase pharmaceutical product. The method includes: isolates the pancreatic kinigenase midbody perfectly, passes it through the QAE-Sepharose Fast Flow that generates the pharamaceutical prodct of the kinigenase by hydronium column chromatographic purification. This pharamaceutical produc approaches high level of purity with 75%, increases the titer to 55 unit / mg and above, and boots up the specific activity to 350 unit / mg albumen and above.

A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and / or delayed thrombin formation.

The present invention relates to an injection containing pegylated kininogenase and its application. The kininogenase does not contain lowly glycosylated KLK1, and the lowly glycosylated KLK1 is KLK1 derived from porcine pancreas The band with the lowest molecular weight among the three bands during SDS-PAGE protein electrophoresis; the general structural formula of the PEG is as shown in formula (1) or formula (2). The pegylated kininogenase formulation of the present invention highly maintains the biological activity of the pegylated kininogenase, has a better protective effect on it, and effectively improves the stability of the drug.

The invention relates to a pancreatic kininogenase and a preparation process thereof. The preparation steps of the pancreatic kininogenase include: thawing frozen porcine pancreas, mincing, grinding, pretreatment, fiber separation, activation, activated pancreatic pulp filtration, 19 steps including alcohol precipitation, heavy phase filtration, granulation, etc., finally obtain pancreatic kininogenase. The present invention realizes the full activation of pancreatic kininogenase and elastase in the pancreas, creating the possibility for the further joint production of pancreatic kininogenase and pancreatic elastase; the activity of pancreatic elastase in the pancreatic kininogenase obtained in the present invention is very high High; the invention greatly improves the filtration speed and realizes industrialized production; the invention adopts the boiling drying method, which has small investment, short time consumption and low energy loss.

The invention relates to PEG-modified medicinal kininogenase and a preparation method and application thereof. The kininogenase does not contain lowly-glycosylated KLK1, and the lowly-glycosylated KLK1 is a stripe with the lowest molecular weight in three stripes during SDS-PAGE protein electrophoresis of porcine pancreas-derived KLK1; PEG adopts a structural general formula shown as a formula (1)or a formula (2). According to the pegylated kininogenase, on one hand, component nonuniformity caused by different glycosylation modifications of the kininogenase is eliminated, so that the purity,the stability, the bioactivity and the medicinal efficacy are improved; on the other hand, after PEG modification of the kininogenase, the half-life period is significantly prolonged, the immunogenicity is significantly reduced, and side effects of a raw medicine are effectively reduced.